CHMP concluded that colistimethate sodium administration is to be restricted to patients with serious infections that have failed other antibiotics or whose treatment options are limited. However, CHMP recommends colistimethate sodium should be given together with other antibiotics whenever possible. To maximize the effect of colistimethate sodium, the antibiotic should be administered with the highest concentration possible for the treated patient, therefore maximizing its action in time. Despite limited data, CHMP issued a table of recommended doses for specific patients, mainly patients with kidney problems and in children. Additionally, it also recommended dosages for adults when the administration route is directly into fluid surrounding the brain or spinal cord. Relative to dosages, CHMP recommended that these should be issued in international units (IU) and a conversion table should be included with product information.
Commissioned by the European Union (EU), CHMP recommendations will now be evaluated, and the EU issues the final report.
http://cysticfibrosisnewstoday.com/2014/10/28/for-cf-patients-polymyxins-come-back-into-style-to-fight-pseudomonas-aeruginosa/
No comments:
Post a Comment